Member Info for SonnyCher

Is Simon Bennett still employed by Avacta? I’ve never seen anything to say that he’d left!

Energyshares ?

All,

Thank you for your kind thoughts and comments - much appreciated. 🤞

VR - thanks for that very encouraging and positive reply. Best wishes.

CJ62 - in reply to your question, I have been under active surveillance since July 2020.

Best wishes.

I have been under active surveillance by Harrogate Hospital for my prostate cancer. Following a raised PSA level and following a subsequent MRI scan this week, I have been given the devastating news that my prostate cancer has spread to some nearby lymph nodes. I am now awaiting results from a CT scan and bone scan to see if it has spread further.

I am seeing the Oncologist in a few weeks time and have started Hormone Treatment in the meantime. I am taking Bicalutamide 50mg tablets for 28 days with a Prostap (Leuprorelin) injection in two weeks time which I’ll have every 3 months.

Do any of the more knowledgeable contributors to this bulletin board have any advice for me and if I wanted to explore the possibility of having AVA6k how to I go about it? Are there any other new treatments for this that anyone is aware of?

My case is one of many which highlights the need for Avacta to enter into JV’s or license their Pre|Cision platform with BP asap.

I am going out for the day to take my mind off things!

Thanks.

£30m is the figure being banded about.

From the RNS of 31 May 2024 it states

“ The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website later that day for shareholders who are not able to attend in person.”

Given that the 2 weekly dosing is taking place in both the US and UK, I wonder if there are more than 3 patients in C2?

The clinical trial mentioned in the following passage about a typical day in the life of Dr William Tap at MSK Cancer Centre was ours!!

“11:15 AM: Jason Chan, one of Dr. Tap’s two medical oncology fellows, pokes his head in the doorway. (Dr. Tap has a general open-door policy.) He’s just met with a patient and wants to give Dr. Tap the rundown. The person is considering leaving her primary oncologist, near her home, and coming to MSK.

The woman has been diagnosed with gastrointestinal stromal tumor (GIST), a rare cancer that develops in the digestive tract. Dr. Tap’s visit with the family lasts nearly 30 minutes. He explains that MSK’s extensive expertise offers the best hope for a positive outcome, but also suggests he can coordinate care with her local oncologist. “What she really needs is to be treated here on a clinical trial,” he says after he leaves her consultation room. But all he can offer today is guidance.”

Outsmarting Sarcoma: How MSK’s Experts Are Advancing Treatment and Research Progress | Memorial Sloan Kettering Cancer Center

If it’s from the Rex RNS on 28 February, surely the 40 days are now up?

I love the reference to pre|CISION-ADC (Aff Drug Conjugate) which have appeared in the Avacta website over the last couple of days and the fact that they are using affimers which have many advantages over the antibodies used in the conventional ADCs which as we know are selling for $billions. It really does look as if they are gearing themselves up!

A quote from the web site

“ The mechanism of action of the pre|CISION-ADC model optimises warhead delivery by targeting the warhead to the TME in two ways: with the antibody or Affimer® target and FAP-release in the TME.“

Exciting times! GLA

Anyone have a link to tonight’s presentation or alternatively where can one watch it?

This is NOT a new drug. It’s a new delivery system.

I’m hoping it’ll stay at around the £1.20 mark as I’m wanting to bed and ISA at the start of the next tax year. This will mean selling as many shares as I can from my trading account around 30 March to allow time for the settlement date to be on or before 5 April. I then intend buying back in my ISA on 6 April, hoping and 🤞that the share price remains at around the level I sold them at. The problem is that the AACR is due to take place in San Diego between 5-10 April. If Avacta are present and divulge more exciting data I’m going to be snookered!! Any suggestions?

I’m also stage 1 prostate cancer and under observation. My local hospital monitor me with 6 monthly tests but having had 2 MRI scans, the last being nearly 2 years ago, are reticent to give me a further MRI scan unless the PSA reading goes up significantly. I was told when I was first diagnosed in 2020 that I’d have a 6 monthly PSA test and an MRI scan every 12 months. This change of policy must be to save costs for the NHS.

It would be great if affimers could be utilised in providing a diagnostic test and as cj62 suggests AVA6k used in small doses to try and kill the tumour before it gets bigger.

I wouldn’t want to be out over the weekend- big news coming soon!

.

Thanks for the replies
I’m not so sure if the advice about ISA held AIM stocks not qualifying is correct.
According to ii their advice is

“ Passing on more wealth

Certain AIM shares qualify for Business Property Relief. This means that after being held for two years, the value of any qualifying AIM shares in your ISA will be excluded from your inheritance tax calculation. You must have held these shares for at least two years and still be holding them on your death for them to qualify for exemption.

Investing in AIM shares via an ISA means that you benefit from tax breaks and your inheritors can receive 100% of the value.”

Am I correct in believing that the value of shares in Avacta are exempt from Inheritance Tax if they’ve been held for more than two years as it’s an AIM listed Company.
For those of us of a certain age and with potential huge gains in the value of our holdings, this is an enormous advantage.
If we were to be listed on NASDAQ presumable this advantage would be lost!